Elsevier

Annals of Oncology

Volume 20, Issue 12, December 2009, Pages 1913-1927
Annals of Oncology

reviews
Triple-negative breast cancer—current status and future directions

https://doi.org/10.1093/annonc/mdp492Get rights and content
Under an Elsevier user license
open archive

Abstract

Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2. It is characterized by distinct molecular, histological and clinical features including a particularly unfavorable prognosis despite increased sensitivity to standard cytotoxic chemotherapy regimens. TNBC is highly though not completely concordant with various definitions of basal-like breast cancer (BLBC) defined by high-throughput gene expression analyses. The lack in complete concordance may in part be explained by both BLBC and TNBC comprising entities that in themselves are heterogeneous. Numerous efforts are currently being undertaken to improve prognosis for patients with TNBC. They comprise both optimization of choice and scheduling of common cytotoxic agents (i.e. addition of platinum salts or dose intensification strategies) and introduction of novel agents (i.e. poly-ADP-ribose-polymerase-1 inhibitors, agents targeting the epidermal growth factor receptor, multityrosine kinase inhibitors or antiangiogenic agents).

Keywords

basal-like breast cancer
gene expression profiling
molecular heterogeneity
targeted agents
triple-negative breast cancer

Cited by (0)